Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) Revenue (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of Revenue data on record, last reported at $1.3 million in Q4 2025.

  • For Q4 2025, Revenue fell 85.94% year-over-year to $1.3 million; the TTM value through Dec 2025 reached $7.8 million, down 58.2%, while the annual FY2025 figure was $7.8 million, 58.19% down from the prior year.
  • Revenue reached $1.3 million in Q4 2025 per ACRS's latest filing, down from $3.3 million in the prior quarter.
  • Across five years, Revenue topped out at $19.0 million in Q3 2022 and bottomed at $1.3 million in Q4 2025.
  • Average Revenue over 5 years is $4.7 million, with a median of $2.1 million recorded in 2023.
  • Peak YoY movement for Revenue: soared 1046.35% in 2022, then tumbled 85.94% in 2025.
  • A 5-year view of Revenue shows it stood at $1.5 million in 2021, then skyrocketed by 416.52% to $7.8 million in 2022, then surged by 126.62% to $17.6 million in 2023, then tumbled by 47.58% to $9.2 million in 2024, then crashed by 85.94% to $1.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Revenue were $1.3 million in Q4 2025, $3.3 million in Q3 2025, and $1.8 million in Q2 2025.